FIRST AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • March 12th, 2024 • Clearside Biomedical, Inc. • Pharmaceutical preparations
This First Amendment to Consulting Agreement (the “Amendment”), effective as of February 17, 2024 (the “Amendment Effective Date”) by and among Dr. Thomas Ciulla (“Consultant”), and Clearside Biomedical, Inc (“Client”), amends the Consulting Agreement dated February 17, 2023 (the “Agreement”). Each of Consultant and Client shall be referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT BY AND BETWEEN BIOCRYST PHARMACEUTICALS, INC. AND CLEARSIDE BIOMEDICAL, INC. November 1, 2023License Agreement • March 12th, 2024 • Clearside Biomedical, Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is entered into as of November 1, 2023 (the “Effective Date”), by and between Clearside Biomedical, Inc., a Delaware corporation with a place of business at 900 North Point Parkway, Suite 200, Alpharetta, Georgia 30004 (“Clearside”) and BioCryst Pharmaceuticals, Inc., a Delaware corporation with a place of business at 4505 Emperor Blvd., Suite 200, Durham NC 27703 (“BioCryst”). Clearside and BioCryst may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDMENT TO THE LICENSE AGREEMENTThe License Agreement • March 12th, 2024 • Clearside Biomedical, Inc. • Pharmaceutical preparations • Georgia
This Fourth Amendment to the License Agreement (the “Fourth Amendment”) is entered into as of January 31, 2024 (the “Fourth Amendment Execution Date”) but effective as of the original Effective Date by and among Emory University (“EMORY”), the Georgia Tech Research Corporation (“GTRC”) and Clearside Biomedical, Inc. (“COMPANY”), each hereinafter referred to as a Party and both hereinafter referred to as “Parties”.
